Premium
Lipella Pharmaceuticals Inc (LIPO)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.27 | 12.1076233184 | 2.23 | 2.61 | 2.16 | 20106 | 2.49605551 | CS |
| 4 | -0.44 | -14.9659863946 | 2.94 | 3.48 | 2.0202 | 56171 | 2.56904257 | CS |
| 12 | -0.62 | -19.8717948718 | 3.12 | 7.31 | 2.0202 | 2447713 | 4.47459379 | CS |
| 26 | -1.1632 | -31.7536580039 | 3.6632 | 7.31 | 2.0202 | 1553428 | 4.15905465 | CS |
| 52 | -3.548 | -58.664021164 | 6.048 | 12 | 2.0202 | 1689904 | 5.59907825 | CS |
| 156 | -53.66 | -95.5484330484 | 56.16 | 61.76 | 2.0202 | 945303 | 8.74061646 | CS |
| 260 | -53.66 | -95.5484330484 | 56.16 | 61.76 | 2.0202 | 945303 | 8.74061646 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
